SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Alibaba Shares Fall as AI Spending Hits Profit 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Add as a preferred source on Google
FREMONT, Calif., May 03, 2018 -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release first quarter 2018 financial and operating results on Wednesday, May 9, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast on May 9, 2018 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and corporate developments.
For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 877-591-4959. For international participants outside the U.S./Canada, the dial-in number is 719-325-2329. For all callers, refer to Conference ID 8804469. To access the live webcast, go to http://asteriasbiotherapeutics.com/inv_events_presentations.php.
A replay of the conference call will be available for one month beginning about two hours after the conclusion of the live call, by calling toll-free (from U.S./Canada) 888-203-1112 ; international callers dial 719-457-0820. Use the Conference ID 8804469. Additionally, the archived webcast will be available at http://asteriasbiotherapeutics.com/inv_events_presentations.php.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with de-myelination and cellular immunotherapies to treat cancer. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC1 (antigen-presenting autologous dendritic cells) is an autologous cancer immunotherapy with promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML). AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic cancer immunotherapy. The company's research partner, Cancer Research UK, plans to begin a first-in-human (FIH) clinical trial of AST-VAC2 in non-small cell lung cancer. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.
Contacts:
Investor Relations
(510) 456-3892
[email protected]
or
EVC Group, Inc.
Michael Polyviou/Greg Gin
(732) 232-6914
[email protected]
